Press Releases

Receive E-mail Alerts
29 January 2019 at 8:30 AM EST
Summary ToggleProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and
7 January 2019 at 7:00 AM EST
Summary ToggleProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached
3 January 2019 at 7:00 AM EST
Summary ToggleProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY .
2 January 2019 at 7:00 AM EST
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track